Incyte

DE - WilmingtonBiotechnology10 H-1B visas (FY2023)

Focus: Incyte is a mid-cap oncology and immunology-focused biopharmaceutical company headquartered in Wilmington, Delaware, with a portfolio built around small-molecule JAK inhibitors and kinase inhibitors.

Oncology Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

Recent layoff filing — 310 affected

8/4/2025 — Spokane Valley, WA · 310 affected · Layoff

Source: state DOL filings via Big Local News

About Incyte

AI assessmentNot Hiring

No open roles listed right now. Follow Incyte to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

1 in 5yr

JAKAFI

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

JAKAFI

Myelofibrosis, Polycythemia Vera, Atopic Dermatitis

$1.9B Part D

LOE Approaching

Help build intelligence for Incyte

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Ruxolitinib

Graft-versus-host Disease (GVHD)

N/A

Clinical Trials (1)

NCT03147742An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

N/A

Vulvovaginal Symptom Questionnaire

Graft Vs Host Disease

N/A

Clinical Trials (1)

NCT06649201Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation

N/A

Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

Chronic Myeloid Leukemia

N/A

Clinical Trials (1)

NCT04048564Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

N/A

Ruxolitinib Cream

Pregnancy Related

N/A

Clinical Trials (1)

NCT06627335An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

N/A

INCB052793

Various

N/A

Clinical Trials (1)

NCT03906344Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis

N/A

Non-Interventional

cGVHD

N/A

Clinical Trials (1)

NCT05919511Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

N/A

Iticitinib

Aplastic Anemia

N/A

Clinical Trials (1)

NCT03906318Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia

N/A

retifanlimab

Squamous Cell Carcinoma of the Anal Canal

N/A

Clinical Trials (1)

NCT06910137An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

N/A

Tafasitamab

Diffuse Large B-cell Lymphoma

N/A

Clinical Trials (1)

NCT04981795realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

N/A

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafa

DLBCL - Diffuse Large B Cell Lymphoma

N/A

Clinical Trials (1)

NCT06299553Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

N/A

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

MPN (Myeloproliferative Neoplasms)

N/A

Clinical Trials (1)

NCT02252159Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

N/A

ONCOLAXY Follow-up

Diffuse Large B Cell Lymphoma

N/A

Clinical Trials (1)

NCT05298293Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma

N/A

Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute

Chronic Myeloid Leukemia

N/A

Clinical Trials (1)

NCT03678454Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

N/A

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

MPN (Myeloproliferative Neoplasms)

N/A

Clinical Trials (1)

NCT02953704Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

N/A

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Chronic Phase Chronic Myelogenous Leukemia

N/A

Clinical Trials (1)

NCT03647215CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

N/A

Vitiligo Registry for Adults and Children in the UK

Dermatologic Disease

N/A

Clinical Trials (1)

NCT06218082Vitiligo Registry for Adults and Children in the UK

N/A

Pemigatinib

Various

N/A

Clinical Trials (1)

NCT03906357Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer

N/A

RUXOLITINIB / INC 424

Myelofibrosis

N/A

Clinical Trials (1)

NCT02469974Ruxolitinib in Combination With Autotransplant

N/A

Ruxolitinib

Erythrocytosis, Familial, 2

N/A

Clinical Trials (1)

NCT01730755Ruxolitinib for Chuvash Polycythemia

N/A

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in S

BCR-ABL Positive Acute Lymphoblastic Leukemia

N/A

Clinical Trials (1)

NCT03515785A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

N/A

Ruxolitinib

Graft-versus-host Disease (GVHD)

N/A

Clinical Trials (1)

NCT05722912Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

N/A

Ruxolitinib

COVID-19

N/A

Clinical Trials (1)

NCT04355793Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

N/A

Ruxolitinib Cream

Pregnancy Related

N/A

Clinical Trials (1)

NCT06259669Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

N/A

axatilimab

Chronic Graft Vs. Host Disease

N/A

Clinical Trials (1)

NCT05544032Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)

N/A

Itacitinib

STAT1 Gain-of-Function Disease

N/A

Clinical Trials (1)

NCT05561985Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease

N/A

INCB054329

Various

N/A

Clinical Trials (1)

NCT03896815Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma

N/A

Microneedle Device

Atopic Dermatitis

N/A

Clinical Trials (1)

NCT06934980A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants

N/A

Virtual exercise and rehabilitation program

Hematopoietic Cell Transplant

N/A

Clinical Trials (1)

NCT05943964Virtual Rehabilitation in HCT

N/A

Parsaclisib

Lymphoma

Phase 1

Clinical Trials (1)

NCT03314922A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Phase 1

INCB001158

Metastatic Cancer

Phase 1

Clinical Trials (1)

NCT02903914Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Phase 1

INCA32459-101

Advanced Malignancies

Phase 1

Clinical Trials (1)

NCT05577182Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

Phase 1

INCB160058

Myeloproliferative Neoplasms

Phase 1

Clinical Trials (1)

NCT06313593A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Phase 1

INCB024360

Solid Tumors and Hematologic Malignancy

Phase 1

Clinical Trials (1)

NCT01195311A Dose-escalation Study in Subjects With Advanced Malignancies

Phase 1

INCB0123667

Solid Tumors

Phase 1

Clinical Trials (1)

NCT05238922Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1

INCA033989

Myeloproliferative Neoplasms

Phase 1

Clinical Trials (1)

NCT06034002A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Phase 1

INCB13739

Insulin Resistance

Phase 1

Clinical Trials (1)

NCT00398619A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

Phase 1

INCB106385

Ovarian Cancer

Phase 1

Clinical Trials (1)

NCT04580485INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Phase 1

INCB099280

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT06039384A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Phase 1

parsaclisib

Advanced Malignancies

Phase 1

Clinical Trials (1)

NCT04831944To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

Phase 1

PF-04634817

Healthy

Phase 1

INCB057643

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT06941077A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants

Phase 1

Stem cell transplantation

Acute Myelogenous Leukemia

Phase 1

Clinical Trials (1)

NCT03755414Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Phase 1

Ruxolitinib

Acute Lymphoblastic Leukemia

Phase 1

Pembrolizumab

Colorectal Cancer (CRC)

Phase 1

Clinical Trials (1)

NCT02646748Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Phase 1

INCAGN02390

Cervical Cancer

Phase 1

Clinical Trials (1)

NCT03652077A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Phase 1

INCB000631

Healthy Participants

Phase 1

Clinical Trials (1)

NCT07039929Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants

Phase 1

Parsaclisib

Breast Cancer

Phase 1

Clinical Trials (1)

NCT04142554Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer

Phase 1

retifanlimab

Locally Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT03059823A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Phase 1

Povorcitinib

Healthy Participants

Phase 1

Clinical Trials (1)

NCT06380205A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Phase 1

INCB099280

Healthy Participants

Phase 1

Clinical Trials (1)

NCT06309394A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants

Phase 1

Incyte

About Incyte

Why Work Here

Key Products

Watch Out For

Products & Portfolio (4)

Key Products by Revenue

Other Products (2)

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)